<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02674347</url>
  </required_header>
  <id_info>
    <org_study_id>W-5107-102</org_study_id>
    <nct_id>NCT02674347</nct_id>
  </id_info>
  <brief_title>MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous Zidebactam in Healthy Adults</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Escalating Doses of Intravenous Zidebactam in Healthy Adult Human Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wockhardt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quintiles, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wockhardt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to evaluate the safety and tolerability of multiple escalating doses of intravenous
      (IV) Zidebactam in healthy adult human subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A double-blind, placebo-controlled study where healthy adult subjects will be randomly
      assigned to receive either of the investigational products (Zidebactam or placebo) in 2
      multiple ascending dose (MAD) cohorts.

      Primary Objective: to evaluate the safety and tolerability of multiple escalating doses of
      intravenous (IV) zidebactam in healthy adult human subjects.

      Secondary Objective: to evaluate the pharmacokinetics (PK) of multiple escalating doses of IV
      zidebactam in healthy adult human subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability will be evaluated by reported AEs, clinical observations, vital signs measurements, and physical examination findings.</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability will be evaluated by 12-lead safety ECG results and clinical laboratory test results</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters -maximum plasma concentration will be evaluated.</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters- area under the plasma concentration-time curve from zero (pre-dose) to 8 hours will be evaluated.</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters- terminal half life etc will be evaluated</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Cohort 1: 3 g or 6 g of Zidebactam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1 (Zidebactam): 3 g of Zidebactam (1 g every 8 hours [q8h]) (n=8) IV infusions administered over 60 minutes.
Cohort 2 (Zidebactam or placebo): 6 g of Zidebactam (2 g q8h) (n=8) IV infusions administered over 60 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cohort 1: Placebo every 8 hours [q8h] (n=2) IV infusions administered over 60 minutes.
Cohort 2: Placebo every q8h (n=2) IV infusions administered over 60 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3 g or 6 g Zidebactam</intervention_name>
    <description>IV for over a duration of 60 minutes</description>
    <arm_group_label>Cohort 1: 3 g or 6 g of Zidebactam</arm_group_label>
    <other_name>WCK 5107</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>IV matching the Investigational drug</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have a body mass index of 18 to 30 kg/m2 (both inclusive) calculated as weight
             (kg)/height (m2).

          2. Medical history without any major pathology/surgery in the last 6 months prior to
             screening.

          3. All values of hematology, serum chemistry, coagulation, and urinalysis showing no
             clinically significant deviations from normal as judged by the Principal Investigator.

          4. Resting supine blood pressure of 90 to 139 (systolic)/40 to 89 (diastolic) mmHg and a
             resting pulse rate of 40 to 100 beats per minute.

          5. Calculated creatinine clearance ≥80 mL/min (Cockcroft-Gault method).

          6. Computerized 12-lead ECG recording without signs of clinically significant pathology
             and showing no clinically significant deviation as judged by the Principal
             Investigator.

        Exclusion Criteria:

          1. History of clinically significant food or drug allergy, including known
             hypersensitivity to β lactam drugs or other related drugs.

          2. History of Clostridium difficile induced diarrhea or infection within 1 year before
             screening

          3. Consumed more than 28 units of alcohol per week at any time in the 6 months before
             investigational product administration

          4. History/evidence of clinically relevant pathology related to the cardiovascular
             system, central nervous system, respiratory tract, gastrointestinal tract,
             endocrinology, immunology, hematology or any other systemic disorder/major surgeries,
             that in the opinion of the Principal Investigator would confound the subject's
             participation and follow-up in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Quintiles</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2016</study_first_submitted>
  <study_first_submitted_qc>February 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2016</study_first_posted>
  <last_update_submitted>August 3, 2016</last_update_submitted>
  <last_update_submitted_qc>August 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

